Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12O2.C4H11NO3 |
| Molecular Weight | 333.3789 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(CO)(CO)CO.OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2
InChI
InChIKey=SWKYVGAYFCGGRP-UHFFFAOYSA-N
InChI=1S/C14H12O2.C4H11NO3/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12;5-4(1-6,2-7)3-8/h1-9H,10H2,(H,15,16);6-8H,1-3,5H2
| Molecular Formula | C4H11NO3 |
| Molecular Weight | 121.135 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H12O2 |
| Molecular Weight | 212.2439 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Felbinac, an active metabolite of fenbufen, is two times more potent than the parent drug. Felbinac is used topically to alleviate pain in the joints and muscles caused by injury or inflammation (Trixam 3% gel or foam). The drug is believed to exert its action by inhibiting COX-2 protein.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | TRAXAM Approved UseTraxam Gel is used for the relief of pain in the joints and muscles caused by injury or inflammation. It is used for the treatment of the following conditions: sprains, strains, bruising, rheumatic or arthritic conditions, frozen shoulder, tennis elbow or other joint injuries. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Biphenylacetate, but not theophylline, lethally interacts with ciprofloxacin in mice. | 1993 Nov |
|
| Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice. | 1993 Sep |
|
| Quantitation of GABAA receptor inhibition required for quinolone-induced convulsions in mice. | 1994 Nov |
|
| Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenyl acetic acid. | 1997 Nov |
|
| Topical non-steroidal drugs are systemically absorbed and may cause renal disease. | 1999 Jan |
|
| Effects of amino acids on the amidation of polyaromatic carboxylic acids by Bacillus cereus. | 2001 Aug |
|
| Inhibitory effect of quinolone antimicrobial and nonsteroidal anti-inflammatory drugs on a medium chain acyl-CoA synthetase. | 2001 Aug 1 |
|
| Intercalation and controlled release of pharmaceutically active compounds from a layered double hydroxide. | 2001 Nov 21 |
|
| Synthetic applications of o- and p-halobenzyl sulfones as zwitterionic synthons: preparation of ortho-substituted cinnamates and biarylacetic acids. | 2002 Jul 26 |
|
| [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration]. | 2002 Jun |
|
| Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer. | 2002 Jun 4 |
|
| Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. | 2004 Jul 2 |
|
| Topical NSAIDs for acute pain: a meta-analysis. | 2004 May 17 |
|
| Changes in brain interleukin-1beta following the coadministration of norfloxacin with biphenylacetic acid in rats. | 2006 Aug 14 |
|
| Pharmaceutical quality control of acid and neutral drugs based on competitive self-assembly in amphiphilic systems. | 2006 Jan |
|
| Synthesis and pharmacological evaluation of some dual-acting amino-alcohol ester derivatives of flurbiprofen and 2-[1,1'-biphenyl-4-yl]acetic acid: a potential approach to reduce local gastrointestinal toxicity. | 2006 Nov |
|
| Percutaneous penetration of felbinac after application of transdermal patches: relationship with pharmacological effects in rats. | 2008 Jan |
|
| Analgesic effect of percutaneously absorbed non-steroidal anti-inflammatory drugs: an experimental study in a rat acute inflammation model. | 2008 Jan 31 |
|
| Stepwise two-color laser photolysis studies of alpha-cleavage in highly excited triplet states of alpha-acyl-4-phenylphenols. | 2008 Jun |
|
| Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents. | 2009 |
|
| Validated LC-MS/MS assay for the determination of felbinac: Application to a preclinical pharmacokinetics study of felbinac trometamol injection in rat. | 2009 Aug 15 |
|
| Separation-oriented derivatization of native fluorescent compounds through fluorous labeling followed by liquid chromatography with fluorous-phase. | 2009 Jun 15 |
|
| Cyclomaltoheptaose mixed esters of anti-inflammatory drugs and short-chain fatty acids and study of their enzymatic hydrolysis in vitro. | 2009 Mar 10 |
|
| Mechanisms of drug release in citrate buffered HPMC matrices. | 2009 Mar 31 |
|
| Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. | 2009 Sep 21 |
|
| Design, synthesis and evaluation of mutual prodrug of 4-biphenylacetic acid and quercetin tetramethyl ether (BPA-QTME) as gastrosparing NSAID. | 2010 Jun |
|
| The suitability of tris(hydroxylmethyl) aminomethane (THAM) as a buffering system for hydroxypropyl methylcellulose (HPMC) hydrophilic matrices containing a weak acid drug. | 2010 Mar 15 |
|
| Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch. | 2010 Nov 10 |
|
| 2-(Biphenyl-4-yl)acetic acid (felbinac). | 2010 Sep 25 |
Sample Use Guides
The usual dose is about one inch or 2.5cm (which is about one gram) of gel rubbed into the affected area two to four times a day.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:00:01 UTC 2023
by
admin
on
Sat Dec 16 14:00:01 UTC 2023
|
| Record UNII |
HA8ZX3VG09
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
935886-64-9
Created by
admin on Sat Dec 16 14:00:02 UTC 2023 , Edited by admin on Sat Dec 16 14:00:02 UTC 2023
|
PRIMARY | |||
|
44238058
Created by
admin on Sat Dec 16 14:00:02 UTC 2023 , Edited by admin on Sat Dec 16 14:00:02 UTC 2023
|
PRIMARY | |||
|
HA8ZX3VG09
Created by
admin on Sat Dec 16 14:00:02 UTC 2023 , Edited by admin on Sat Dec 16 14:00:02 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|